Online citations, reference lists, and bibliographies.

Bone Mineral Density And Bone Turnover In Non-cirrhotic Patients With Chronic Hepatitis C And Sustained Virological Response To Antiviral Therapy With Peginterferon-alfa And Ribavirin

E. Redondo-Cerezo, F. Casado-Caballero, J. L. Martin-Rodriguez, J. Hernández‐Quero, F. Escobar-Jiménez, J. L. González-Calvín
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
SummaryPatients with chronic hepatitis C have low bone mineral density and increased bone resorption related to serum transaminase levels. Elevated serum soluble tumor necrosis factor (sTNFR-55) receptor levels may play a role in the bone mass loss in these patients. Bone mass is improved and bone turnover normalized in patients who respond to antiviral therapy with interferon and ribavirin.IntroductionLow bone mineral density (BMD) has been described in patients with chronic hepatitis C (HCV). The study objective was to evaluate the effect of antiviral therapy on BMD and bone metabolism in non-cirrhotic HCV patients with sustained virological response.MethodsWe conducted a prospective study in 36 consecutive outpatients from the general community with non-cirrhotic HCV and an early and sustained virological response to peginterferon-alfa and ribavirin therapy. Determinations of BMD (dual X-ray absorptiometry at lumbar spine and femoral neck) and biochemical measurements of bone metabolism and sTNFR-55 were made at baseline, after 24 and 48 weeks of antiviral therapy, and at 48 weeks after the end of treatment.ResultsPatients had a significantly reduced BMD, which significantly increased during the follow-up. Serum levels of sTNFR-55 and bone turnover markers were increased at baseline and significantly reduced at all subsequent time points. We found an inverse correlation between BMD and both serum aminotransferase levels and urine deoxypyridinoline (D-pyr) and a positive correlation between serum aminotransferases and both urine D-Pyr and serum sTNFR-55.ConclusionsPatients with chronic hepatitis C have low bone mass associated with increased bone resorption, and some relationship can be expected between serum aminotransferase levels and the degree of bone mass loss. Bone mass may be improved and bone turnover normalized in patients who respond to antiviral therapy. Elevated serum sTRFR-55 levels may play a role in the bone mass loss of these patients.
This paper references
The TNF receptor in TNF-mediated cytotoxicity.
F. Kull (1988)
10.1084/jem.175.2.323
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
D. Aderka (1992)
10.1016/0016-5085(89)90783-X
Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease.
T. Diamond (1989)
10.3748/WJG.V11.I12.1843
Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection.
I. Schiefke (2005)
10.7326/0003-4819-104-6-893_1
Bone disease in alcohol abuse.
D. Bikle (1985)
10.1210/JC.2004-0077
Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis.
J. L. González-Calvín (2004)
10.1007/s00223-004-0175-0
Ribavirin, but Not Interferon α-2b, is Associated with Impaired Osteoblast Proliferation and Differentiation In Vitro
R. O. Moreira (2004)
10.1053/JHEP.2003.50106
Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy
T. Berg (2003)
Bonemineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? BMC Gastroenterol
A Gur (2005)
10.1016/S0168-8278(00)80314-1
Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C.
J. Solís-Herruzo (2000)
10.1016/S0016-5085(03)01062-X
AGA technical review on osteoporosis in hepatic disorders.
W. Leslie (2003)
10.1016/0016-5085(95)90694-0
Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection.
G. Marinos (1995)
Morphologic basis of bone mineral measurement: transient and steady-state effects of treatment in osteoporosis
AM Parfitt (1980)
10.1515/pteridines.2000.11.2.43
Neopterin, soluble receptors for interleukin-2 and tumor necrosis factor in viral cirrhosis and alcoholic cirrhosis
J. González-Calvín (2000)
10.1002/JBMR.5650040116
Interleukin‐1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro
Johannes Pfeilschifter (1989)
10.7326/0003-4819-122-7-199504010-00024
Reviews and Notes: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis
L. Alexeeva (1994)
10.1053/JHEP.2002.33711
Lack of evidence for ribavirin‐induced bone loss
A. Trombetti (2002)
10.1002/JBMR.5650080714
Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis
M. Seibel (1993)
[Interleukin 1 and tumor necrosis factor].
C. Herzog (1987)
Study of bone mineral density in lumbar spine and femoral neck in a Spanish population . Multicentre Research Project on Osteoporosis
AM Parfitt (1994)
10.1002/HEP.510280315
Bone mineral density, serum insulin‐like growth factor I, and bone turnover markers in viral cirrhosis
F. Gallego-Rojo (1998)
10.1111/j.1365-2893.2008.01038.x
Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon α and ribavirin therapy
W. Hofmann (2008)
10.1016/j.ajpath.2012.03.023
Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.
Michelle Wilkison (2012)
10.1007/BF01623462
Study of bone mineral density in lumbar spine and femoral neck in a Spanish population
M. D. Curiel (2005)
10.1530/EJE.0.1320251
New markers of bone metabolism: clinical use in metabolic bone disease.
E. Eriksen (1995)
10.1111/j.1600-0609.1988.tb00220.x
A tumor necrosis factor binding protein is present in human biological fluids
C. Peetre (1988)
10.1210/endo-129-3-1596
Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast development and subsequent resorption of mineralized matrix.
G. van der Pluijm (1991)
10.1186/1471-230X-5-30
Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
A. Gur (2005)
and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation
JL Gonzalez-Calvin (2004)
10.1002/hep.1840190629
Classification of chronic hepatitis: Diagnosis, grading and staging
V. Desmet (1994)
10.1136/gut.50.suppl_1.i1
Guidelines on the management of osteoporosis associated with chronic liver disease
J. Collier (2002)
10.1002/HEP.1840210414
Neopterin and soluble tumor necrosis factor receptor type I in alcohol‐induced cirrhosis
A. Díez-Ruiz (1995)
10.1007/s002239900205
Osteoporosis and Bone Mineral Metabolism Disorders in Cirrhotic Patients Referred for Orthotopic Liver Transplantation
A. Monegal (1997)
10.1016/j.jhep.2011.01.035
Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection.
Diala El-Maouche (2011)
10.1038/319516a0
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors
D. Bertolini (1986)
10.1007/s00223-012-9653-y
Association Between Chronic Hepatitis C Virus Infection and Bone Mineral Density
J. Lin (2012)
10.1055/S-2007-1007291
Histological classification and quantitation of the severity of chronic hepatitis: keep it simple!
Prodromos Hytiroglou (1995)



This paper is referenced by
10.1097/MCG.0000000000001091
Outcomes of Patients With Cirrhosis Undergoing Orthopedic Procedures
Neehar D. Parikh (2018)
10.1097/QAD.0000000000000363
Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis
Huan V. Dong (2014)
10.1016/J.APJTB.2016.11.027
Clinical correlations between chronic hepatitis C infection and decreasing bone mass density after treatment with interferon-alpha
Vahid Babaei (2017)
10.1002/9781119266594.CH60
Human Immunodeficiency Virus and Bone
Michael T. Yin (2018)
10.20471/acc.2017.56.03.19
Hepatic Osteodystrophy: A Global (Re)View of the Problem.
Ecaterina-Constanța Barbu (2017)
10.1097/COH.0000000000000259
Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture
R. Bedimo (2016)
10.1590/2359-3997000000015
Association of primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with clear cell renal carcinoma.
Letícia da Silva Gomes (2015)
10.15403/jgld.2014.1121.253.hpc
Body Composition Changes in Patients with Chronic Hepatitis C.
E. C. Barbu (2016)
10.5603/EP.2015.0005
Growth hormone/insulin-like growth factor-1 axis, calciotropic hormones and bone mineral density in young patients with chronic viral hepatitis.
B. Marek (2015)
10.1089/aid.2015.0204
Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients
Roger G Bedimo (2016)
10.1007/s00198-017-4354-z
Bone density and microarchitecture in hepatitis C and HIV-coinfected postmenopausal minority women
M T Yin (2017)
10.1007/s11904-016-0341-9
HIV and Bone Complications: Understudied Populations and New Management Strategies
Michael T. Yin (2016)
Semantic Scholar Logo Some data provided by SemanticScholar